These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17093260)

  • 1. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
    Armamento-Villareal R; Napoli N; Panwar V; Novack D
    N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260
    [No Abstract]   [Full Text] [Related]  

  • 2. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 3. Anabolic therapy in glucocorticoid-induced osteoporosis.
    Sambrook PN
    N Engl J Med; 2007 Nov; 357(20):2084-6. PubMed ID: 18003966
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
    Mersereau JE; Khouri C; Jaffe RB
    Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
    Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
    Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
    Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evidence of alendronate treatment for osteoporosis].
    Harada A
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():337-43. PubMed ID: 18161127
    [No Abstract]   [Full Text] [Related]  

  • 9. Alendronate prevents development of the skeletal changes induced by azathioprine in rats.
    Cegieła U; Kaczmarczyk-Sedlak I; Pytlik M; Folwarczna J; Nowińska B; Fronczek-Sokół J
    Acta Pol Pharm; 2013; 70(2):309-15. PubMed ID: 23614287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate: preclinical studies.
    Rodan GA
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):50S-52S. PubMed ID: 9273938
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug injury in the upper gastrointestinal tract: effects of alendronate.
    Khapra AP; Rose S
    Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
    N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decimal point--osteoporosis therapy at the 10-year mark.
    Strewler GJ
    N Engl J Med; 2004 Mar; 350(12):1172-4. PubMed ID: 15028820
    [No Abstract]   [Full Text] [Related]  

  • 14. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring pharmacological therapy for osteoporosis.
    Lewiecki EM
    Rev Endocr Metab Disord; 2010 Dec; 11(4):261-73. PubMed ID: 20143165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant osteoclast formation and long-term oral bisphosphonate therapy.
    Roos JC; Cox TM
    N Engl J Med; 2009 Apr; 360(16):1676-7; author reply 1677-8. PubMed ID: 19373965
    [No Abstract]   [Full Text] [Related]  

  • 18. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
    Aggarwal HK; Jain D; Chhabra P; Yadav RK
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Jul; 39(1):5-13. PubMed ID: 30110263
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.